The use of risankizumab after poor response to 2 interleukin-17 inhibitors, secukinumab, and ixekizumab, was safe and effective in plaque psoriasis.

Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying antirheumatic drugs.

EP0031/A400 is being developed jointly by Ellipses in a global clinical phase 1/2 trial under the name EP0031 (NCT05443126) ...

Studies have suggested that IL-1 beta activation leads to IL-6 production, which could provide an alternative to current therapeutic strategies.

Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically ...

US biopharma Vertex Pharmaceuticals today announced results from its Phase II study of suzetrigine, an investigational, oral, ...

Interleukin Inhibitors market is estimated to be valued at USD 32.60 Bn in 2024 and is expected to reach USD 74.81 Bn by 2031, exhibiting a CAGR of 12.6%. Mr. Shah Coherent Market Insights Pvt. Ltd.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

A recent study by Columbia University has revealed that ACE inhibitors, one of the most commonly prescribed medications for ...

A recent study by Columbia University has found that one of the most commonly prescribed medications for high blood pressure, ...

and in the sum of boxes of the Clinical Dementia Rating Scale (CDR-SB).² Alzheimer Disease FDA Approves Acetylcholinesterase ...

Analysis of the top key players operating in the Water Treatment Chemicals Market: Akzo Nobel N.V: ...